Recro Pharma Company Profile (NASDAQ:REPH)

About Recro Pharma (NASDAQ:REPH)

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:REPH
  • CUSIP: N/A
  • Web: www.recropharma.com
Capitalization:
  • Market Cap: $171.73 million
  • Outstanding Shares: 19,059,000
Average Prices:
  • 50 Day Moving Avg: $8.45
  • 200 Day Moving Avg: $7.76
  • 52 Week Range: $5.81 - $10.17
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.46
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $69.99 million
  • Price / Sales: 2.44
  • Book Value: $2.99 per share
  • Price / Book: 2.99
Profitability:
  • EBITDA: ($13,040,000.00)
  • Net Margins: -46.75%
  • Return on Equity: -56.04%
  • Return on Assets: -19.40%
Debt:
  • Debt-to-Equity Ratio: 0.40%
  • Current Ratio: 5.81%
  • Quick Ratio: 5.23%
Misc:
  • Average Volume: 82,709 shs.
  • Beta: -0.53
  • Short Ratio: 9.7
 

Frequently Asked Questions for Recro Pharma (NASDAQ:REPH)

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma, Inc. (NASDAQ:REPH) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.48) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.06. The firm had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.90 million. Recro Pharma had a negative net margin of 46.75% and a negative return on equity of 56.04%. View Recro Pharma's Earnings History.

When will Recro Pharma make its next earnings announcement?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Wednesday, November, 8th 2017. View Earnings Estimates for Recro Pharma.

Where is Recro Pharma's stock going? Where will Recro Pharma's stock price be in 2017?

5 brokers have issued 1 year price objectives for Recro Pharma's shares. Their forecasts range from $6.50 to $20.00. On average, they expect Recro Pharma's share price to reach $13.50 in the next year. View Analyst Ratings for Recro Pharma.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:

  • Wayne B. Weisman J.D., Independent Chairman of the Board
  • Geraldine A. Henwood Ph.D., President, Chief Executive Officer, Director
  • Michael Celano, Chief Financial Officer
  • Jyrki Mattila M.D. Ph.D., Executive Vice President - Business Development
  • Ryan D. Lake, Senior Vice President - Finance, Chief Accounting Officer
  • Randall Mack, Senior Vice President - Development, Secretary
  • Diane Myers, Senior Vice President - Regulatory and Quality
  • Fred Graff, Chief Commercial Officer
  • Stewart McCallum M.D., Chief Medical Officer
  • Alfred Altomari, Independent Director

How do I buy Recro Pharma stock?

Shares of Recro Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of Recro Pharma stock can currently be purchased for approximately $8.95.


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)
Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  143 (Vote Outperform)
Underperform Votes:  87 (Vote Underperform)
Total Votes:  230
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Recro Pharma (NASDAQ:REPH) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $13.50 (50.84% upside)
Consensus Price Target History for Recro Pharma (NASDAQ:REPH)
Price Target History for Recro Pharma (NASDAQ:REPH)
Analysts' Ratings History for Recro Pharma (NASDAQ:REPH)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/31/2017Roth CapitalSet Price TargetBuy$20.00LowView Rating Details
7/25/2017Piper Jaffray CompaniesSet Price TargetBuy$11.00HighView Rating Details
6/14/2017Janney Montgomery ScottDowngradeBuy -> Fair Value$21.00 -> $6.50HighView Rating Details
3/27/2017AegisReiterated RatingBuy$11.00LowView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Recro Pharma (NASDAQ:REPH)
Earnings by Quarter for Recro Pharma (NASDAQ:REPH)
Earnings History by Quarter for Recro Pharma (NASDAQ REPH)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.73)N/AView Earnings Details
8/10/2017Q2 2017($0.54)($0.48)$14.90 million$16.93 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.58)($0.42)$15.58 million$18.74 millionViewN/AView Earnings Details
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13$13.00 million$16.75 millionViewN/AView Earnings Details
11/13/2015Q3($0.20)($0.24)$16.54 millionViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Recro Pharma (NASDAQ:REPH)
2017 EPS Consensus Estimate: ($2.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.65)($0.65)($0.65)
Q2 20171($0.60)($0.60)($0.60)
Q3 20171($0.61)($0.61)($0.61)
Q4 20171($0.69)($0.69)($0.69)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Recro Pharma (NASDAQ:REPH)
Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 65.06%
Insider Trades by Quarter for Recro Pharma (NASDAQ:REPH)
Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)
Insider Trades by Quarter for Recro Pharma (NASDAQ:REPH)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/14/2017James E FlynnInsiderSell110,447$6.39$705,756.33View SEC Filing  
6/13/2017James E FlynnMajor ShareholderSell32,447$6.59$213,825.73View SEC Filing  
6/12/2017James E FlynnMajor ShareholderSell10,000$6.74$67,400.00View SEC Filing  
6/8/2017James E FlynnInsiderSell62,868$7.06$443,848.08View SEC Filing  
5/12/2017Stonepine Capital Management,Major ShareholderSell510,000$7.40$3,774,000.00View SEC Filing  
5/11/2017Stonepine Capital Management,Major ShareholderSell244,629$7.65$1,871,411.85View SEC Filing  
5/4/2017Stonepine Capital Management,Major ShareholderSell217,308$7.70$1,673,271.60View SEC Filing  
3/16/2017Scp Vitalife Partners Ii LpMajor ShareholderSell44,977$8.00$359,816.00View SEC Filing  
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.97View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.00View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.00View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.00View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.20View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.00View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Recro Pharma (NASDAQ:REPH)
Latest Headlines for Recro Pharma (NASDAQ:REPH)
Source:
DateHeadline
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 2:40 PM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:18 AM
streetinsider.com logoRecro Pharma (REPH) Reports Phase III IV Meloxicam Clinical ... - StreetInsider.com
www.streetinsider.com - October 11 at 7:05 AM
finance.yahoo.com logoRecro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting
finance.yahoo.com - October 11 at 7:05 AM
finance.yahoo.com logoETFs with exposure to Recro Pharma, Inc. : October 9, 2017
finance.yahoo.com - October 10 at 6:21 AM
finance.yahoo.com logoRecro Pharma, Inc. :REPH-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
finance.yahoo.com - October 7 at 7:53 AM
finance.yahoo.com logoRecro Pharma to Participate in Upcoming Investor Conferences
finance.yahoo.com - October 6 at 6:28 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Expected to Announce Quarterly Sales of $13.93 Million
www.americanbankingnews.com - October 1 at 3:16 AM
americanbankingnews.com logoAnalyzing Recro Pharma (REPH) & OVID THERAPEUTC (OVID)
www.americanbankingnews.com - September 30 at 6:36 PM
globenewswire.com logoRecro Pharma Reports Inducement Grants for New Staff Nasdaq ... - GlobeNewswire (press release)
globenewswire.com - September 29 at 11:45 AM
thestreet.com logoRecro Pharma Announces FDA Acceptance For Review Of New Drug Application For IV Meloxicam 30mg
www.thestreet.com - September 28 at 9:33 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 2:58 PM
globenewswire.com logoRecro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017 - GlobeNewswire (press release)
globenewswire.com - September 6 at 7:35 AM
finance.yahoo.com logoRecro Pharma Presents Phase III IV Meloxicam Clinical Safety and Opioid Use Data at PAINWeek® 2017
finance.yahoo.com - September 6 at 7:35 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Expected to Post Quarterly Sales of $14.42 Million
www.americanbankingnews.com - August 25 at 9:02 AM
finance.yahoo.com logoLannett (LCI) Q4 Earnings In Line, Stock Up on Solid View
finance.yahoo.com - August 24 at 11:53 AM
globenewswire.com logoRecro Pharma Appoints Jyrki Mattila as Executive Vice President of Business Development - GlobeNewswire (press release)
globenewswire.com - August 23 at 10:40 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - August 22 at 2:40 PM
americanbankingnews.com logoRecro Pharma, Inc. (NASDAQ:REPH) Announces Earnings Results
www.americanbankingnews.com - August 11 at 12:17 PM
finance.yahoo.com logoRecro Pharma reports 2Q loss
finance.yahoo.com - August 11 at 8:00 AM
finance.yahoo.com logoRecro Pharma Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:20 AM
americanbankingnews.com logo Analysts Anticipate Recro Pharma, Inc. (NASDAQ:REPH) to Post -$0.53 Earnings Per Share
www.americanbankingnews.com - August 5 at 7:08 AM
finance.yahoo.com logoRecro Pharma Submits New Drug Application for IV Meloxicam 30mg
finance.yahoo.com - August 1 at 5:41 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Given a $20.00 Price Target at Roth Capital
www.americanbankingnews.com - July 31 at 3:32 PM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 28 at 2:51 PM
americanbankingnews.com logoPiper Jaffray Companies Analysts Give Recro Pharma, Inc. (REPH) a $11.00 Price Target
www.americanbankingnews.com - July 26 at 11:59 PM
americanbankingnews.com logoRecro Pharma, Inc. (NASDAQ:REPH) Short Interest Update
www.americanbankingnews.com - July 16 at 7:23 AM
americanbankingnews.com logo$14.90 Million in Sales Expected for Recro Pharma, Inc. (NASDAQ:REPH) This Quarter
www.americanbankingnews.com - July 15 at 7:34 AM
americanbankingnews.com logoRecro Pharma, Inc. (NASDAQ:REPH) Expected to Post Earnings of -$0.53 Per Share
www.americanbankingnews.com - July 13 at 10:20 PM
bizjournals.com logoMalvern pharma firm acquires experimental pain medicines from Cornell
www.bizjournals.com - July 6 at 8:25 AM
streetinsider.com logoRecro Pharma (REPH) Reports Acquisition of Novel Neuromuscular Blocking Agents
www.streetinsider.com - July 6 at 8:25 AM
globenewswire.com logoRecro Pharma Acquires Novel Neuromuscular Blocking Agents - GlobeNewswire (press release)
globenewswire.com - July 5 at 10:04 AM
finance.yahoo.com logoRecro Pharma Acquires Novel Neuromuscular Blocking Agents
finance.yahoo.com - July 5 at 10:04 AM
americanbankingnews.com logoRecro Pharma, Inc. (REPH) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - July 3 at 2:49 PM
globenewswire.com logoRecro Pharma Reports Inducement Grants for New Staff - GlobeNewswire (press release)
globenewswire.com - June 16 at 3:30 PM
globenewswire.com logoRecro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference - GlobeNewswire (press release)
globenewswire.com - June 16 at 9:19 AM
feeds.benzinga.com logoRecro Pharma to Participate in Hospital Drug Launch Panel at the JMP Life Sciences Conference
feeds.benzinga.com - June 16 at 7:52 AM
seekingalpha.com logoRecro Pharma (REPH) Presents At Jefferies 2017 Global Healthcare Conference
seekingalpha.com - June 9 at 7:41 PM
streetinsider.com logoRecro Pharma (REPH) Appoints Ryan Lake as CAO - StreetInsider.com
www.streetinsider.com - June 7 at 8:50 AM
streetinsider.com logoRecro Pharma (REPH) Appoints Ryan Lake as CAO
www.streetinsider.com - June 6 at 8:59 PM
investorplace.com logoCumberland Pharmaceuticals, Inc. (CPIX) and Recro Pharma Inc (REPH) Lead 9 Notable Investor Filings - Investorplace.com
investorplace.com - May 24 at 9:48 AM
investorplace.com logoCumberland Pharmaceuticals, Inc. (CPIX) and Recro Pharma Inc (REPH) Lead 9 Notable Investor Filings
investorplace.com - May 22 at 10:31 AM
streetinsider.com logoForm 8-K Recro Pharma, Inc. For: May 18 - StreetInsider.com
www.streetinsider.com - May 21 at 12:03 AM
benzinga.com logoExclusive: Recro Pharma CEO Talks Meloxicam Non-Opioid Product Ahead Of APS Annual Meeting
www.benzinga.com - May 17 at 7:27 PM
globenewswire.com logoRecro Pharma to Present Phase III Bunionectomy Clinical Data for ... - GlobeNewswire (press release)
globenewswire.com - May 16 at 7:23 PM
streetinsider.com logoRecro Pharma (REPH) Reports Top-Line Results from Phase III Safety Study of IV Meloxicam - StreetInsider.com
www.streetinsider.com - May 11 at 8:17 AM
globenewswire.com logoRecro Pharma Reports First Quarter 2017 Financial Results - GlobeNewswire (press release)
globenewswire.com - May 11 at 8:17 AM
streetinsider.com logoRecro Pharma (REPH) Reports Top-Line Results from Phase III Safety Study of IV Meloxicam
www.streetinsider.com - May 9 at 10:49 AM
seekingalpha.com logoRecro Pharma (REPH) Presents At Oppenheimer 27th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 23 at 8:00 PM
biz.yahoo.com logoRECRO PHARMA, INC. Files SEC form 10-K, Annual Report
biz.yahoo.com - March 9 at 7:31 PM

Social

Chart

Recro Pharma (REPH) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.